Background: Since the introduction of endovascular repair (EVR) for infrarenal abdominal aortic aneurysm (AAA), clinical evaluation has been under way in many countries throughout the world. The main purpose of this retrospective study was to determine outcome of EVR with aortic endovascular prostheses (AEPs) and to evaluate the extent to which French practitioners have complied with regulatory and clinical guidelines for the use of these trial devices.
Abdominal aortic aneurysm (AAA) is a life-threatening condition predominantly affecting men over 60 years of age. The overall prevalence of AAA larger than 45 mm in men older than 50 years is estimated to be 6%, and a number of studies [1] [2] [3] [4] suggest that incidence is increasing. The overall mortality rate for ruptured AAA is about 80%, and only about half of the patients who undergo emergency operation will survive. 2, 5 As increasing aneurysm diameter is a major predictor of rupture, the current therapeutic approach to AAA calls for surveillance or repair according to diameter. According to guidelines published in 1999 by the French Agency for Accreditation and Evaluation in Health (ANAES, French acronym) 6 and in 2001 by the French Agency for Sanitary Safety of Health Products (AFSSAPS, French acronym), 7 the critical diameter for repair is 50 mm. However, recent randomized studies 8, 9 have shown no significant difference in mortality between patients receiving regular ultrasound scanning follow-up and those receiving immediate treatment for aneurysms between 40 and 55 mm in diameter.
For more than 40 years, surgery was the only available method of repair for AAA. In the literature, mean postoperative mortality for elective surgery has been less than 5% 10 and morbidity was 13% in a cohort of 1135 consecutive patients. 11 The long-term outcome of open surgical repair (OSR) of AAA is excellent. The incidence of late graft complications has been low, ranging from 4% at 38 months 11 to 7% at 5 years. 12 In 1991, Parodi et al 13 described the first endovascular repair (EVR) of AAA with an aortic endovascular prosthesis (AEP) for AAA. The primary goal of this approach is exclusion of the aneurysm from the circulation in the hope that the risk of subsequent rupture will be significantly reduced. The main benefits of EVR versus OSR are a shorter hospital stay, lower morbidity, and quicker recovery. 14 Since the first successful minimally invasive procedure was reported, a great interest in EVR has developed throughout the world. Manufacturers began intense research and development programs to design stent grafts. Practitioners began to place more and more of these devices for treatment of aortic and peripheral vascular aneurysms. According to the voluntary registry of the French Society of Vascular Surgery (SCV, French acronym), a total of 944 AEPs were inserted in France between 1991 and 1999: 841 for infrarenal aortic aneurysm and 103 for thoracic aortic aneurysm. These figures are probably underestimations because they correspond to responses from only 262 of the 389 French SCV members (67.3%) invited to participate in the SCV registry.
As elsewhere, preliminary experience in France has shown that EVR is not devoid of morbidity and risks. Many initial problems were caused by device-related defects involving graft materials, attachment systems, and delivery systems. 15 Another early lesson was the need for careful patient selection based on the morphologic features because insufficient neck length, excessive tortuosity, inadequate femoral or iliac access, and severe calcification can prevent deployment. 16 Preliminary experience also showed that EVR not only shared some of the same potential adverse outcomes as OSR but also added a few of its own. The main EVR-specific problem is development of type I and type II endoleaks involving pressurized blood flow into the aneurysmal sac that can lead to aneurysm growth and rupture. 14, 15, 17 Mainly because of concerns about the long-term reliability of endovascular repair, in March 1999, the ANAES in France published a regulatory document 6 stating that EVR for AAA was not an approved technique and providing clear guidelines for the use of AEPs (Table  I) . As a consequence, EVR was subject to the Huriet Act (Law 88-1138 of December 1988) protecting the rights of individuals participating in biomedical research. 6 The two major requirements of the Huriet Act involve informed consent from patients and payment of trial costs by the trial initiator.
Despite these guidelines, the AFSSAPS reported severe incidents in France involving the use of AEPs in April 1999 and December 2000 and re-emphasized the requirement that patients undergoing EVR were subject to ANAES constraints (Table I ). In compliance with European Directive 93/42 EEC of June 1993, the AFSSAPS also conducted a thorough study to evaluate the safety of all AEPs on the market in June 2000 and defined the conditions for their use. On the basis of (1) preclinical in vitro and in vivo data, (2) clinical data, (3) risk analysis, and (4) sterilization procedures, the AFSSAPS recommended that further limitations be put on EVR procedures in France in terms of both approved devices and conditions for their use. 7 In 2000, the results of limited studies by the French National Health Insurance Fund for Salaried Workers (CNAMTS, French acronym) suggested that some practitioners at both public and private institutions in France were not complying with the guidelines of ANAES. Consequently, CNAMTS decided to undertake a comprehensive retrospective survey to evaluate postoperative complications after placement of AEPs in France and the extent to which French practitioners have complied with guidelines of the ANAES 6 for the use of these trial devices. The purpose of this report is to describe the findings of that study.
PATIENTS AND METHODS
Work group. This study was designed to allow impartial analysis independent of administrative, commercial, or political interests. It was conducted by a work group of CNAMTS medical advisors under direction of the Head of the CNAMTS Medical Service Department. CNAMTS is Cases involving EVR for AAA using AEP must be reported to the national registry. If the AEP is removed, it must be sent to an independent laboratory for examination in cooperation with the manufacturer who developed the AEP.
the Healthcare Financing Administration that covers health care costs for roughly 80% of the French population. All CNAMTS medical advisors are nonpracticing physicians responsible for overseeing medical cost reimbursements. None of the medical advisors in the work group attended an EVR or investigated a procedure carried out in an institution where he or she had formerly practiced. Study findings were presented to the surgeon, who was free to provide any corrections or addendums that he or she deemed necessary. Data collection. Data were collected from the medical files of all patients who underwent an EVR for AAA in France from June 1, 1999 to May 31, 2001 . A list of all public and private centers performing vascular surgery or interventional radiology or cardiology was compiled. To ensure the validity of this list, it was checked at the regional level on the basis of information from local CNAMTS medical advisors, records of each center's activities, and requests for reimbursement of AEP by practitioners as per internal CNAMTS memorandum 1912-1997. In addition, the computerized patient and data tracking (PMSI, French acronym) coding system (Diagnostic Related Groups) was searched to identify institutions caring for patients with aortic aneurysms. Two search requests were used. The first was aortic aneurysm as principal diagnosis in association with ten International Classification of Diseases codes (171.0 to 171.9) and the so-called "surgical" Homogenous Groups of Patients (GHM, French acronym) in Diagnosis Category (CMD) 05 (GHM 158, 159, 160, 168, 172) . The second search also used aortic aneurysm as the principal diagnosis but in association with group 880 of the Major Category (CM 24), corresponding to immediate death. These computer searches were designed to ensure identification of any institution that had admitted more than 15 AAA patients per year.
Every procedure involving insertion, reinsertion, or ablation of an AEP was recorded on a data spreadsheet. To ensure that no procedure was overlooked, medical advisors met with the pharmacy and sterile medical devices committees and the head of the medical device vigilance department to obtain a list of all reported devices and accidents. They also consulted operating-room registers and compulsory registers for the procedures performed in radiology suites.
Data analysis. Data analysis involved information about clinical setting, patients, practitioners, clinical findings, and compliance with guidelines for AEP use. Clinical data included patient characteristics, preoperative evaluation, and adverse outcomes distinguishing between those related to "device or procedure" and other complications. Assessment of guideline compliance involved informed consent, research protocol, use of European Community (CE)-marked devices, and reporting of any medical device incident to the vigilance committee of the AFSSAPS.
Statistical analysis. Statistical analysis was performed with Microsoft Excel (Microsoft Corp, Redmond, Wash) and SPSS (SPSS Inc, Chicago, Ill) software. Variables were cross-checked, and queries were sent to regional project directors concerning missing or aberrant data. Any procedures with a "no answer" rate higher than 25% were excluded from statistical analysis. The Pearson 2 test was used to compare percentages for qualitative variables. Means with calculation of 95% percent confidence (CI) interval and standard deviation (SD) were used for the analysis of quantitative variables.
RESULTS

Clinical setting.
During the 2-year study period, a total of 1012 AEPs were deployed in France for treatment of AAA, including 930 procedures (92%) at 46 public centers and 62 procedures (8%) at 19 private institutions. Table II shows the distribution of these procedures according to region and type of facility. Three regions-Ile-de-France, Provence-Alpes-Cǒ te-d'Azur, and Rhǒne-Alpes,accounted for 60% of procedures (n ϭ 614). The number of AEPs inserted for EVR of AAA was 1 at 9 centers (14%), 2 to 10 at 37 centers (57%), 11 to 50 at 23 centers (35%), 51 to 100 at 2 centers (5%), and over 100 (3%) at 2 centers. It was difficult to determine how many devices had been inserted by each practitioner, for several reasons. Many procedures were performed by two physicians working together. Some practitioners had operating privileges in several institutions, both public and private, or were often involved in teaching. Furthermore, this study was not designed to assess the training of the practitioners.
Patient characteristics. Most patients (93.6%; n ϭ 947) were men. As shown in Table III , mean patient age was 72 Ϯ 9 years (range, 33 to 99 years). The patient was older than 70 years in 642 cases (63.4%). On the basis of associated risk factors mentioned in the medical records, it was possible to classify 853 patients (84%) according to the American Society of Anesthesiologists (ASA) system (Table  IV) . There were 313 patients (36.7%) in ASA I or II, 438 (51.3%) in ASA III, and 102 (11.2%) in ASA IV or V. According to medical records, patients in ASA IV or V were treated out of "compassion." The overall mean duration of hospital stay was 9 Ϯ 8 days, with a median of 8 days.
Preoperative evaluation. All patients underwent imaging for morphologic assessment of their AAA, including spiral computed tomography (CT) scans in 913 out of 986 cases (92.6%) and digitized angiography with placement of a graduated catheter in the aneurysm in 909 out of 975 cases (93.2%). Angiography was performed more often in the public (855/903) than in the private (54/72) sector (P ϭ .001; odds ratio [OR] 5.9; 95% CI, 3.2 to 10.9). Discussion of the indication for EVR in a radiology-vascular surgery staff meeting was documented in only 227 cases (22.7%).
The location of the aneurysm was clearly defined in the patient's medical file in 956 cases (94%). The neck of the aneurysm was infrarenal with moderate iliac dilation in 948 cases (93.7%). Infrarenal AAA was associated with common iliac aneurysms ranging in diameter from 25 to 30 mm in eight patients (0.8%). The exact location of the AAA could not be determined from the patient's medical file in 56 cases (6%).
Maximum AAA diameter was specified in the patient's medical record in 904 cases (89.4%). As shown in Table V , 280 AAAs (31%) had a diameter less than 50 mm. All of these patients were symptom-free except four, who complained of abdominal pain. In four patients, the aneurysm had expanded by 10 mm or more over a 12-month period. The diameter of the aneurysm was reported to be exactly 50 mm in 145 cases (16.0%). The remaining 479 patients (53.0%) had aneurysms larger than 50 mm.
Type of procedure and devices. The type of the endovascular procedure performed was clearly noted in the patient's medical file in 930 cases (92%). It consisted of first-time EVR in 881 cases (95%), insertion of an additional AEP in 34 cases (3.6%), and ablation of an AEP with conversion to open repair in 15 cases (1.4%). Reintervention was significantly more frequent (P ϭ .004, OR: 3.7, 95% CI: 1.6 to 8.6) in private (8/82) than in public institutions (26/930).
Bifurcated stent grafts were used in 74.8% of cases, aortouniiliac stent grafts in 15.6%, and aortoaortic stent grafts in 9.6%. Table VI shows the different AEP models used. Ten different devices were employed, including nine stent grafts manufactured by different companies and one made-to-measure stent graft. Only one of the commercially available devices used in this study had not received CE approval-the Vanguard III system (Boston Scientific, Natick, Mass), which was used seven times in an unapproved clinical trial at the same institution. Custom-made stent grafts constructed by the surgeons accounted for 12.3% of all the endovascular prostheses inserted. These devices, consisting of Z auto-expandable stainless steel stents connected with commercially available polyester vas- cular grafts, were sterilized the day before surgery and loaded into the introducer during the implantation procedure. 18 Various additional procedures were performed in association with AEP insertion. Iliac or femoral bypass, iliac or femoral endarterectomy, or another vascular intervention was performed in 285 patients (28.2%). Additional procedures were not considered to be complication-related un-less specifically designated as such in the patient's medical file.
Surveillance of the aortic endovascular prostheses. Immediate and 1-year follow-up data (mean duration, 345 Ϯ 230 days) were available in the medical records of 987 patients (97.5%; 95% CI, 96.3 to 98.3%) and demonstrated poor compliance with recommendations issued by the AN-AES 6 on follow-up after EVR with AEP. These recommen- dations are similar to those issued by the Food and Drug Administration for investigations involving cardiovascular devices in the United States. 19 Follow-up procedures carried out in the hospital during the immediate recovery period included discharge angiography in 894 patients (91%), CT scan with contrast media in 726 patients (74%), and plain abdominal radiograph views in 724 patients (73%). Only 385 patients (39%) underwent complete imaging studies as recommended by the regulatory authorities and described in Table I . Follow-up surveillance procedures carried out during the first 6 months after the procedure included duplex scan in 513 patients (52%) and CT scan with contrast media in 529 patients (53,6%). Only 294 patients (30%) underwent complete imaging studies as recommended by the ANAES. 6 Although some patients living far from the primary treatment center may have undergone follow-up surveillance at outside centers, study data indicate that 184 patients (18.6%) underwent no surveillance.
Complications. Complications were clearly described in the patient's medical file in 891 cases (88%). As shown in Table VII , complications occurred during the first 30 postoperative days in 122 patients (13.7%, 95% CI: 11.6 to 16.1%), including 27 deaths (3.1%, 95% CI: 2 to 4.4%). At the end of 1 year (Table VII) , including the first 30 postoperative days, complications had occurred in a total of 177 patients (19.9%, 95% CI, 17.4 to 22.7%) with 47 deaths (5.3%), including 20 (2.2%) device-or procedure-related deaths. Complications were directly related to the procedure or to the device in 15.3% and unrelated in 4.6%. A total of 142 endoleaks were reported. Treatment for endoleak included conversion to open operation in 15 cases, endovascular re-intervention to insert a new endovascular prosthesis in 22, and embolization in 30 (Tables VII and  VIII) . Additional treatment for endoleak was either not performed (69 cases) or not specified (6 cases).
Compliance with guidelines for EVR with AEP. As mentioned above, the 1999 ANAES guidelines (Table I) required that all EVRs with AEP be carried out within a clinical trial setting with written informed consent. Data compiled in this study showed that only 151 patients (14.9%, 95% CI: 12.8 to 17.2%) were included in a clinical research protocol. Of the remaining 861 patients treated outside investigational settings, only 149 (17.3%) signed informed consent forms.
The CNAMTS medical advisors also analyzed compliance with technical and medical aspects of the ANAES guidelines (Table I ). The results demonstrated that 896 (93.2%) AEPs were inserted in a facility having at least one interventional radiologist and one vascular surgeon on staff. In addition, 946 (94.4%) of the procedures were performed in an operating or procedure room complying with ANAES guidelines.
For the 1012 patients studied, only six device vigilance reports were sent to the AFSSAPS. These reports accounted for only 4.4% of 136 "device or procedure" complications and 30% of 20 deaths related to "device or procedure."
DISCUSSION
Since the first successful EVR in 1991, 13 an increasing number of AEPs have been used for treatment of AAA in France and elsewhere. This exhaustive study based on data collected by thorough study of each patient's file by CNAMTS medical advisors provides important insight not only into the outcome of EVR with AEPs for management of AAA but also into the way that these devices are currently being used and evaluated in France.
This study provided interesting data on various outcomes of EVR, including mean hospital stay, 30-day mortality, and 1-year procedure-or device-related complications and deaths. The mean duration of hospitalization for EVR in this survey was 9 days. The shortest mean hospital stays for EVR in France were 6 Ϯ 2.5 days in the study of Becquemin et al 20 and 7.8 Ϯ 2.3 days in the study of Ricco et al. 21 The mean duration of hospitalization for OSR of 22 Thus, this study appears to confirm that mean duration of hospitalization after EVR is shorter than after OSR. However, it should be noted that hospitalization after both EVR and OSR are longer in France than in North America. 11, 22 Analysis of this study indicated that the 30-day mortality rate after EVR was 3.1%. Although underestimation cannot be ruled out because postoperative information was missing in 178 medical records (18%), this rate is comparable with rates reported after EVR in the Eurostar registry (3.2%). 14 In multicenter studies on OSR, mortality rates have ranged from 2.7% to 4.9%. It was 2.7% in Lederle's randomized study 9 and 4.9% in France. 22, 24 Preliminary findings from the Lifeline registry indicate that the 1-year mortality rate of 14.9% for EVR is comparable with that of OSR (12.6%) in a comparable group. 25 In our study, the 1-year complication rate after EVR was 19.9%. This seems high but comparison with OSR 10 is difficult because the type and, above all, timing of complications are different after EVR. In fact, 1-year complications after AEP insertion may have been underestimated in this study because the mean follow-up period was only 345 days.
The major finding of this study involves poor compliance with regulatory requirements and clinical guidelines for the use of AEPs. Four out of five AEPs were inserted outside of an investigational setting, without informed patient consent in 82.7% of cases. To justify their choice, many practitioners have argued that such procedures were licit because the devices used carried the CE-approval mark. This argument is specious because the CE mark corresponds to safety and quality standards rather than to clinical benefit. To clarify this situation, the AFSSAP 7 issued guidelines in 2001 specifying that only three of the eight AEPs carrying the CE mark were approved for clinical use under strict follow-up protocol. This study provides further evidence that EVR is still experimental.
The findings of this study also indicate that French practitioners of EVR with AEP have disregarded classic indications for AAA repair as well as recommendations for long-term follow-up after EVR with AEP. Fully 31% of the AEPs used in France during the 2-year study period were inserted in patients with AAAs measuring less than 50 mm in diameter. According to published consensus guidelines confirmed by two randomized studies, 8, 9 lesions less than 55 mm are indicated for surveillance rather than repair. Only 294 patients (30%) underwent follow-up surveillance, including complete imaging studies as recommended by the ANAES, 6 and 184 (18.6%) patients underwent no follow-up surveillance. On a more positive note for most French practitioners, compliance with guidelines concerning the need to perform EVR in an operative environment and immediate postoperative monitoring were generally good.
Several hypotheses can be proposed to explain noncompliance of French practitioners with legislative and clinical requirements for EVR with AEPs. The main reason involves the fact that penalties were initially rarely applied. In the absence of penalties, enthusiasm for a new minimally invasive technology and its short-term benefits may blind many French practitioners to the still-experimental nature of this technique and the need for caution concerning its long-term efficacy.
Some practitioners may also have acted under pressure from patients who had learned of EVR with AEP from the mass public media or the Internet. However it should be said in this regard that 3 years ago, at the time of this study, much less medical information on the Internet was available in French than in English and that French patients were much less inclined to use the Internet as a source of such information than their American counterparts. In any case, availability of information on new technology would not have freed practitioners from their duty to inform patients of the risks and comply with regulatory requirements for the use of a new medical procedure.
It is unlikely that financial interests played a major role in practitioner's therapeutic decision-making because most AEPs (92%, n ϭ 930) were inserted in public hospitals where financing comes from the global hospital endow- Two important points should be made regarding financing of EVR in France. The first is that the Huriet Act protects patients from incurring any expense related to clinical investigation. According to French law, the trial initiator is responsible for all research-related expenses, ie, the cost of the device or drug being tested and any additional examinations or procedures required by its use, as well as for obtaining insurance to cover patient risk. The Healthcare Financing Administration covers only expenses corresponding to regular treatment expenses for the patient's condition. This cost-sharing system between the trial initiator and the Healthcare Financing Administration has worked better for drug trials implicating large pharmaceutical firms than for medical device research, which often involves firms with more limited resources. Financing requirements in France that may have encouraged some manufacturers to carry out clinical research in countries with more favorable policies should be improved in the future.
The second important point concerning financing of EVR in France is that in practice public hospital endowment funds have paid for AEPs more often than Research Instigators. Public health practitioners have justified their decision to devote public funds to AEPs on the basis that clinical research is an important part of the public hospital teaching function. However, analysis of accountancy reports shows that such outlays are rarely reported as research-related expenses. This finding suggests that there is a tendency for some public officials to treat AEP insertion as a routine rather than an experimental procedure. This attitude is in agreement with the failure of practitioners to perform EVR in an investigational setting.
The Huriet Act may have been perceived by French practitioners as an unnecessary administrative impediment to rapid application of a new medical technology. This perception may have been reinforced in the minds of private practitioners by access to endowment funds for financing AEPs in the public sector, which may have been perceived as an unfair advantage. However, there is no reason to think that the Huriet Act is impractical or incompatible with current medical views and patient demands. Although financing of clinical trials for medical device remains a problem in France, the French system provides the same regulatory framework for clinical investigation as the US investigational device exemption system in the United States. 19 Devices must obtain CE approval on the basis of in vitro bench testing and in vivo animal model research in compliance with International Standards Organization standards. 7 Trial protocols must be authorized by an ethics committee. Signed informed consent must be obtained from patients. Furthermore, the Huriet Act has encoun-tered no problems for therapeutic drug trials in France, and the French system served as the basis for defining the April 4, 2001 European Community good clinical practices for human therapeutic trials.
Several other findings of this study deserve comment. There was a significant difference between the number of AEPs used in public and private hospitals. Three possible explanations can be given for this finding. The most likely reason is that, as stated previously, French regulations preventing reimbursement of EVR to private practitioners favor public centers where CE-approved devices can be financed through the facility's annual endowment. In this regard, it should be emphasized that patients are not deprived of treatment because French university public hospitals are considered as reference centers open to all. The second possible explanation is that some smaller private hospitals were overlooked in this study despite every attempt to avoid omitting any EVR because centers treating fewer than 15 AAAs per year were excluded. The third explanation is that publication of ANAES guidelines discouraged private centers from performing EVR.
Another finding is the significantly higher re-intervention rate in private institutions. This difference could have been related to the lower number of procedures performed by private practitioners (4.3 patients per center) as compared with public practitioners (20.3 patients per center). This could have created an experience gap, which placed the private sector lower on the learning curve. This possibility is supported by the fact that the public and private patient populations were similar with regard to gravity of disease and type of aortic aneurysm.
Nine institutions in this study implanted only one AEP for AAA during the 2-year study period. A possible explanation for this daunting finding is that some practitioners used EVR to enhance their image. Like the experience-gap problem mentioned in the previous paragraph, use of EVR for self-promotion constitutes a sound argument for limiting EVR trials to a few public and private centers. These public and private centers could be chosen depending on number of patients with treated AAAs, results of conventional open repair, and expertise in endovascular techniques.
The problems described herein demonstrate that previous attempts to organize development of new medical technologies in France have so far failed. In the 1990s, the CNAMTS unsuccessfully proposed the "single bookingoffice" approach to medical research in which all parties involved-government, scientific societies, manufacturers, health financing administration, and health care agencieswould select techniques for evaluation and define the modalities of study and financing. In 1997, the CNAMTS (ENSM decree 1912-1997) decided to encourage clinical studies within the framework of the Huriet Act in the private sector and the French Society of Vascular Surgery set up an independent AEP register. The law of July 8, 1998 mandated the mission of evaluating medical devices to the AFSSAPS, but this agency was initially better suited to device vigilance than clinical evaluation.
The main question raised by this study is what can be done to ensure first that the fundamental rules on human experimentation and professional ethics are respected in public and private practice in France and second that valuable trial data are no longer lost because of noncompliance with legislative and clinical requirements for clinical research. In July 2001, the AFSSAPS issued a statement 7 that basically confirmed the guidelines proposed by the ANAES in 1999 6 and recommended use of AEPs only for high-risk patients with aneurysms having a diameter greater than 50 mm or expanding at a rate greater than 1 cm per year. However, this belated action has had no effect on the situation. Hope for the future may lie in the upcoming harmonization of French and European legislation. This process could provide more flexibility in financing policy defined by the Huriet Act and lead to stricter protection of patient rights. In summary, this survey demonstrates that EVR with AEP for AAA has not been properly used in France and that clinical evaluation of AEPs has not been carried out in accordance with recommendations of the ANAES agency. 6 Development of new technologies involving medical devices continues to pose a major challenge in France. In the future, a better cooperation between different national authorities involved in the process and between the European competent authorities shall improve the evaluation of these new technologies.
